Posted: February 1, 2013 at 11:46 am
Super Smash Bros. Brawl with Friends [January 21st] Battle 10 (Shadow Moses Island)
Wario eats SandBag. Wario eats Assist Trophy. Wario eats a ball of unmutated stem cells. Man, Wario eats everything!!
By: GingerDragon87
Read the rest here:
Super Smash Bros. Brawl with Friends [January 21st] Battle 10 (Shadow Moses Island) - Video
Posted: February 1, 2013 at 11:46 am
A Heart cell derived from IPSCs beating
Short video of a heart cell beating. The cell is derived from induced pluripotent stem cells. Source: Movie S2 from Uosaki H, Fukushima H, Takeuchi A, Matsuoka S, Nakatsuji N, Yamanaka S, Yamashita J. "Efficient and Scalable Purification of Cardiomyocytes from Human Embryonic and Induced Pluripotent Stem Cells by VCAM1 Surface Expression Check out Stem Cells Freak at http://www.stemcellsfreak.com for more stem cell information and news
By: Filotheos Xoleras
See the article here:
A Heart cell derived from IPSCs beating - Video
Posted: February 1, 2013 at 11:46 am
Sunrise - Stem cell miracle cream
Skin products using plant stem cells are emerging as the latest miracle product for ageing skin.
By: SunriseOn7
Posted: February 1, 2013 at 11:46 am
Can We Delay The Clamping Of The Umbilical Cord?
The Insception Lifebank Cord Blood Program is Canada #39;s largest and most experienced program of its kind, committed in its dedication to store umbilical cord blood and maintain viable stem cells. Families across the world are choosing to preserve their baby #39;s cord blood in order to take advantage of the medical advancements that cord blood has the potential to provide. For more information please visit: http://www.insception.com http http://www.twitter.com
By: Insception
See the original post here:
Can We Delay The Clamping Of The Umbilical Cord? - Video
Posted: February 1, 2013 at 11:46 am
About Maureen At Insception Lifebank Cord Blood Program
The Insception Lifebank Cord Blood Program is Canada #39;s largest and most experienced program of its kind, committed in its dedication to store umbilical cord blood and maintain viable stem cells. Families across the world are choosing to preserve their baby #39;s cord blood in order to take advantage of the medical advancements that cord blood has the potential to provide. For more information please visit: http://www.insception.com http http://www.twitter.com
By: Insception
See more here:
About Maureen At Insception Lifebank Cord Blood Program - Video
Posted: February 1, 2013 at 11:46 am
Conversations: ethics, science, stem cells
Human embryonic stem cell lines are generated from blastocysts - early human embryos. But what are blastocysts, and when does personhood begin? What justifies research? Doctors, scientists, ethicists, theologians and a patient bring their different points of view, in this thought-provoking exploration of the ethical issues surrounding stem cell research. Visit http://www.eurostemcell.org for more information, news and educational resources.
By: EuroStemCell
See the rest here:
Conversations: ethics, science, stem cells - Video
Posted: February 1, 2013 at 10:47 am
MINNEAPOLIS--(BUSINESS WIRE)--
Ground breaking research on cancer stem cells as targets and normal stem cells in Immunotherapy will be discussed at the 2nd Annual Cancer Immunotherapy Conference in Washington DC on April 4-5, 2013.
As modern oncology, largely directed towards developing therapies that achieve tumor reduction, has been thus far unsuccessful in achieving long term management of cancer, much more needs to be done in identifying and appropriately leveraging targets associated with tumor initiation, relapse or metastasis. Immunotherapy holds the promise of achieving durable control of cancer if matched with appropriate targets borne by cancer cells responsible for relapse and metastasis.
At the 2nd Annual Cancer Immunotherapy Conference, significant findings on hematopoietic stem cells and T cell engineering for cancer immunotherapy, as well as cancer stem cells as a new category of targets for immune intervention in solid and hematological malignancies will be presented by nearly twenty experts in the fields of academia, pharmaceuticals and cancer research.
Speakers and panelists will be addressing and answer the following questions:
Some of the speakers at this years conference include:
This conference brings together leading scientists and C-Level executives from across the globe to present ground breaking research, case studies and new viewpoints. Please visit http://www.cancerimmunotherapyconference.com for the full list of speakers, agenda, and registration information.
See original here:
Cutting Edge Research in Stem Cells and Cancer Immunotherapy to Be Presented at the 2nd Annual Cancer Immunotherapy ...
Posted: February 1, 2013 at 10:47 am
By Alex Y. Vergara
DR. VICKI Belo ARNOLD ALMACEN
Is the elusive search for the fountain of youth over? Vicki Belo, one of the countrys leading beauty doctors, thinks so, as she recently unveiled her latest weapons in the fight against aging: intradermal (ID) and intravenous (IV) stem cell treatments.
Developed by Russian doctors in Moscow after more than a decade of research, ID treatment, much like Botox, is injected directly on specific points of the face and neck to supposedly facilitate faster skin regeneration, tighten sagging muscles and promote the production of collagen and elastin, two of the skins most important building blocks.
As we age, our skin tends to lose elasticity, said Belo. Since we dont produce as much collagen and elastin as we used to, our faces soon lose fat and become hollow. Wrinkles also start to deepen and permanently set in.
This may sound a bit scary, but the stem cells Belo uses, unlike those used in a number of clinics abroad, including a famous one in Germany, dont come from animals like sheep. They are not sourced from embryos either.
In a way, we pioneered stem cell therapy in the Philippines by using a persons own fat cells and transferring them to other parts of her body, particularly the face, said Belo. We still do that, but this latest development in stem cell therapy is more effective and offers more dramatic results.
Instead, Belo now uses stem cells cultured from bone marrow harvested from young and healthy Russian donors using the so-called Mesenchymal procedure.
Stem cells sourced from bone marrow are much better, she explained. Bone marrow is like the bodys main factory where stem cells originate.
More effective approach
Read more:
Bone marrow stem cells (from young Russians!)–the new fountain of youth?
Posted: February 1, 2013 at 10:47 am
Toronto, Feb 1 (IANS) Stem cells from zebrafish, the staple of genetic research, could regenerate damaged cones in retinas and restore eyesight to people.
Rods and cones in the eyes are the most important photoreceptors. In humans, rods provide night vision, while cones offer a full-colour look at the world during the day.
It was not known, says University of Alberta researcher Ted Allison, whether stem cells could be instructed to only replace the cones in its retina. This could have important implications for human eyesight, the journal Public Library of Science ONE reports.
Almost all success in regenerating photoreceptor cells to date had been limited to rods, not cones. Most previous experiments were conducted on nocturnal rodents, animals that require good night vision and have far more rods than cones, according to an Alberta statement.
"This is the first time in an animal research model that stem cells have only repaired damaged cones," said Allison. "For people with damaged eyesight, repairing the cones is most important because it would restore day-time colour vision.
Researchers say this shows some hope for stem cell therapy that could regenerate damaged cones in people, especially in the cone-rich regions of the retina that provide daytime/colour vision.
Allison says the next step for his team is to identify the particular gene in zebrafish that activates repair of damaged cones.
Posted: February 1, 2013 at 10:46 am
Jan. 31, 2013 New research has shown the presence of a disease affecting small blood vessels, known as microangiopathy, in the bone marrow of diabetic patients. While it is well known that microangiopathy is the cause of renal damage, blindness and heart attacks in patients with diabetes, this is the first time that a reduction of the smallest blood vessels has been shown in bone marrow, the tissue contained inside the bones and the main source of stem cells.
These precious cells not only replace old blood cells but also exert an important reparative function after acute injuries and heart attacks. The starvation of bone marrow as a consequence of microangiopathy can lead to a less efficient healing in diabetic patients. Also, stem cells from a patient's bone marrow are the most used in regenerative medicine trials to mend hearts damaged by heart attacks. Results from this study highlight an important deficit in stem cells and supporting microenvironment that can reduce stem cells' therapeutic potential in diabetic patients.
The research team, led by Professor Paolo Madeddu, Chair of Experimental Cardiovascular Medicine in the School of Clinical Sciences and Bristol Heart Institute at the University of Bristol, investigated the effect of diabetes on bone marrow stem cells and the nurturing of small blood vessels in humans.
The new study, published in the American Heart Association journal Circulation Research, was funded by the British Heart Foundation (BHF).
The researchers have shown a profound remodelling of the marrow, which shows shortage of stem cells and surrounding vessels mainly replaced by fat, especially in patients with a critical lack of blood supply to a tissue (ischaemia). This means that, as peripheral vascular complications progress, more damage occurs in the marrow. In a vicious cycle, depletion of bone marrow stem cells worsens the consequences of peripheral ischaemia.
Investigation of underpinning mechanisms revealed that exposure of bone marrow stem cells to the high glucose level typical of diabetes mellitus impacts on "microRNAs," which are tiny RNA molecules controlling gene expression and hence biological functions. In particular, microRNA-155, that normally controls the production of stem cells, becomes dramatically reduced in bone marrow cells exposed to high glucose. Diabetes-induced deficits are corrected by reintroducing microRNA-155 in human stem cells. The authors foresee that microRNAs could be used to regain proper stem cells number in diabetes and fix stem cells before reintroduction into a patient's body.
Professor Paolo Madeddu said: "Our study draws attention to the bone marrow as a primary target of diabetes-induced damage. The research suggests that the severity of systemic vascular disease has an impact on bone marrow causing a precocious senescence of stem cells. More severe bone marrow pathologies can cause, or contribute to, cardiovascular disease and lead to worse outcomes after a heart attack, through the shortage of vascular regenerative cells. Clinical evidence indicates that achieving a good control of glucose levels is fundamental to prevent vascular complications, but is less effective in correcting microangiopathy. We need to work hard to find new therapies for mending damaged microvessels."
Professor Costanza Emanueli, Chair of Vascular Pathology and Regeneration at the University of Bristol and co-author of the paper, added: "MicroRNAs represent an attractive means to repair the marrow damage and generate "better" stem cells for regenerative medicine applications. We are working at protocols using microRNA targeting for enhancing the therapeutic potential of stem cells before their transplantation to cure heart and limb ischaemia, which are often associated with diabetes mellitus. More work is, however, necessary before using this strategy in patients."
The findings advance the current understanding of pathological mechanisms leading to collapse of the vascular niche and reduced availability of regenerative cells. The data provides a key for interpretation of diabetes-associated defect in stem cell mobilisation following a heart attack. In addition, the research reveals a new molecular mechanism that could in the future become the target of specific treatments to alleviate vascular complications in patients with diabetes.
Professor Jeremy Pearson, Associate Medical Director at the BHF said: "Professor Madeddu and his team have shown for the first time that the bone marrow in patients with diabetes can't release stem cells which are important for the repair of blood vessel damage commonly found in people with the disease.
Read more from the original source:
Diabetes distresses bone marrow stem cells by damaging their microenvironment
